16 Participants Needed

ABBV-101 for Healthy Adults

AC
Overseen ByABBVIE CALL CENTER
Age: 18+
Sex: Any
Trial Phase: Phase 1
Sponsor: AbbVie
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

This study will assess the effect of food (high fat) on oral ABBV-101 and how ABBV-101 moves through the body in healthy adult participants

Research Team

AI

ABBVIE INC.

Principal Investigator

AbbVie

Eligibility Criteria

This clinical trial is for healthy adults with a Body Mass Index (BMI) between 18.0 and 32.0. Participants should be in good health as determined by medical history, physical exams, vital signs, lab tests, and an ECG.

Inclusion Criteria

My BMI is between 18.0 and 32.0.
I am generally healthy based on recent medical exams.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Treatment

Participants receive ABBV-101 under fasting and non-fasting conditions in two periods

21 days

Follow-up

Participants are monitored for safety and effectiveness after treatment

24 days

Treatment Details

Interventions

  • ABBV-101
Trial Overview The study is testing ABBV-101 taken orally to see how food intake, specifically high-fat meals, affects its absorption and movement through the body of healthy participants.
Participant Groups
2Treatment groups
Experimental Treatment
Group I: ABBV-101: Sequence 2Experimental Treatment1 Intervention
Participants will receive ABBV-101 under non-fasting conditions in Period 1 and will receive ABBV-101 under fasting conditions in Period 2.
Group II: ABBV-101: Sequence 1Experimental Treatment1 Intervention
Participants will receive ABBV-101 under fasting conditions in Period 1 and will receive ABBV-101 under non-fasting conditions in Period 2

Find a Clinic Near You

Who Is Running the Clinical Trial?

AbbVie

Lead Sponsor

Trials
1,079
Recruited
535,000+
Founded
2013
Headquarters
North Chicago, USA
Known For
Immunology treatments
Top Products
Humira (adalimumab), Skyrizi (risankizumab), Rinvoq (upadacitinib)

Dr. Roopal Thakkar

AbbVie

Chief Medical Officer since 2023

MD from Wayne State University School of Medicine

Robert A. Michael profile image

Robert A. Michael

AbbVie

Chief Executive Officer

Bachelor's degree in Finance from the University of Illinois

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of ServiceยทPrivacy PolicyยทCookiesยทSecurity